Sanchez‐Escuredo 2015.

Methods	Study design: open‐label, parallel RCT Duration of study: 2009 to 2011 Duration of follow‐up: 12 months
Participants	Country: Spain Setting: single centre Inclusion criteria: kidney transplant recipients aged 50 to 75 years; kidney function with CrCl > 30 mL/min/1.73 m2; at least 12 months post transplant; iPTH > 60 pg/mL; T‐score < ‐1 Number: treatment group (35); control group (34) Mean age ± SD (years): treatment group (63 ± 12); control group (64 ± 10) Sex (M/F): treatment group (7/28); control group (4/30) Exclusion criteria: DM; primary hyperthyroidism
Interventions	Treatment group Ibandronate (oral): 150 mg/month Control group Risedronate (oral): 35 mg/week Co‐interventions Calcium carbonate: 2500 mg/d Vitamin D3: 800 IU/d
Outcomes	Change in serum calcium, iPTH, and alkaline phosphatase Kidney function (eGFR) Change in BMD at lumbar spine and femoral neck
Notes	Funding source: not reported Trial registration: not reported
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Insufficient information to permit judgement
Allocation concealment (selection bias)	Unclear risk	Insufficient information to permit judgement
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Incomplete outcome data (attrition bias) All outcomes	High risk	8/69 patients did not complete the study due to treatment‐related side effects
Selective reporting (reporting bias)	High risk	Patient important outcomes not captured or reported systematically
Other bias	Low risk	Study appears free of other biases